Compare Stocks

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$0.20 -1.0%	$0.31	$0.19 ▼ $3.35	$2.15M	2.67	376,710 shs	87,128 shs
CYCC Cyclacel Pharmaceuticals	$1.78 -3.8%	$2.35	$1.52 ▼ $13.20	$2.35M	0.54	131,945 shs	10,326 shs
ENVB Enveric Biosciences	$0.88 -6.1%	$1.04	$0.65 ▼ $6.98	$6.42M	0.85	3.63 million shs	126,289 shs
EVOK Evoke Pharma	$0.47 -2.2%	$0.62	$0.42 ▼ $2.42	$3.97M	0.22	56,073 shs	1,943 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	+0.24%	-14.58%	-40.75%	-73.71%	-88.42%
CYCC Cyclacel Pharmaceuticals	-5.13%	-4.64%	-21.28%	-12.32%	-81.86%
ENVB Enveric Biosciences	+6.35%	+3.04%	-21.18%	-14.73%	-48.60%
EVOK Evoke Pharma	-12.79%	-11.35%	-21.38%	-37.82%	-77.20%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	1.2855 of 5 stars	3.3	5.0	0.0	0.0	0.0	0.0	0.6
ENVB Enveric Biosciences	1.6018 of 5 stars	3.5	3.0	0.0	0.0	2.2	0.0	0.6
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	2.50	Moderate Buy	$21.00	1,079.78% Upside
ENVB Enveric Biosciences	3.00	Buy	$10.00	1,035.59% Upside
EVOK Evoke Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CNSP, EVOK, CYCC, and ENVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
1/30/2024	ENVB Enveric Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	($0.71) per share	N/A
CYCC Cyclacel Pharmaceuticals	$420K	5.59	N/A	N/A	$0.57 per share	3.12
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$0.71 per share	N/A
EVOK Evoke Pharma	$5.18M	0.77	N/A	N/A	($0.77) per share	-0.61

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNSP CNS Pharmaceuticals	-$18.85M	-$5.66	N/A	∞	N/A	N/A	-603.40%	-421.35%	5/20/2024 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$27.22	N/A	N/A	N/A	N/A	-448.19%	-151.29%	5/9/2024 (Estimated)
ENVB Enveric Biosciences	-$17.29M	-$8.11	N/A	N/A	N/A	N/A	-349.01%	-187.74%	5/20/2024 (Estimated)
EVOK Evoke Pharma	-$7.79M	-$2.33	N/A	∞	N/A	-150.43%	-517.99%	-91.83%	5/20/2024 (Estimated)

Latest CNSP, EVOK, CYCC, and ENVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/19/2024	Q4 2023	CYCC Cyclacel Pharmaceuticals	-$6.35	-$6.23	+$0.12	-$6.23	N/A	$0.03 million
3/14/2024	Q4 2023	EVOK Evoke Pharma	N/A	-$0.59	-$0.59	-$0.59	N/A	$1.68 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNSP CNS Pharmaceuticals	N/A	0.26	0.26
CYCC Cyclacel Pharmaceuticals	N/A	0.91	0.91
ENVB Enveric Biosciences	N/A	1.53	1.53
EVOK Evoke Pharma	N/A	2.25	2.09

Ownership

Institutional Ownership

Company	Institutional Ownership
CNSP CNS Pharmaceuticals	14.02%
CYCC Cyclacel Pharmaceuticals	23.58%
ENVB Enveric Biosciences	13.82%
EVOK Evoke Pharma	N/A

Insider Ownership

Company	Insider Ownership
CNSP CNS Pharmaceuticals	3.88%
CYCC Cyclacel Pharmaceuticals	8.47%
ENVB Enveric Biosciences	3.00%
EVOK Evoke Pharma	11.78%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CNSP CNS Pharmaceuticals	3	10.64 million	10.22 million	Not Optionable
CYCC Cyclacel Pharmaceuticals	2,018	1.32 million	1.21 million	Optionable
ENVB Enveric Biosciences	7	7.29 million	7.08 million	Not Optionable
EVOK Evoke Pharma	4	8.48 million	7.48 million	Not Optionable

CNSP, EVOK, CYCC, and ENVB Headlines

Source	Headline
	Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average of $0.93 americanbankingnews.com - April 18 at 3:26 AM
	Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com americanbankingnews.com - April 18 at 2:30 AM
	Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications finance.yahoo.com - April 17 at 10:11 AM
	Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications globenewswire.com - April 17 at 8:30 AM
	DelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 \| DelveInsight finanznachrichten.de - April 10 at 7:22 PM
	Empowering students: Innovative approaches to climate change education msn.com - April 10 at 9:21 AM
	Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team finance.yahoo.com - April 10 at 9:21 AM
	Evoke Pharma (NASDAQ:EVOK) Stock Passes Below Two Hundred Day Moving Average of $0.96 americanbankingnews.com - April 10 at 4:32 AM
	Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com americanbankingnews.com - April 10 at 2:18 AM
	How a Dubai man built a $200,000 art collection in his Business Bay home msn.com - April 1 at 9:18 PM
	The Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-Cola msn.com - March 30 at 10:47 PM
	Brain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlert msn.com - March 30 at 7:37 AM
	Evoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer finanznachrichten.de - March 22 at 8:55 AM
	Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer marketwatch.com - March 21 at 5:34 PM
	Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer finance.yahoo.com - March 21 at 5:34 PM
	Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer globenewswire.com - March 21 at 4:15 PM
	‘Saving animals is ethical, it’s evocative. And it’s smart business’ timesofindia.indiatimes.com - March 19 at 1:56 AM
	Big change is the only constant in eco: India Inc msn.com - March 18 at 10:54 AM
	BU study reveals key to combating high-risk neuroblastoma news-medical.net - March 17 at 8:08 PM
	Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript seekingalpha.com - March 17 at 12:09 AM
	Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic? finance.yahoo.com - March 16 at 2:08 PM
	Brain gain: Hope rises with new dementia treatments msn.com - March 15 at 9:08 PM
	Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 15 at 4:06 PM
	Evoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results finanznachrichten.de - March 15 at 11:04 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CNS Pharmaceuticals

NASDAQ:CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Cyclacel Pharmaceuticals

NASDAQ:CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Enveric Biosciences

NASDAQ:ENVB

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Evoke Pharma

NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial